14 results on '"Liu, Jinxia"'
Search Results
2. Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma
- Author
-
Cui, Xiaopeng, Lin, Zhipeng, Chen, Yuyan, Mao, Xiaofei, Ni, Wenkai, Liu, Jinxia, Zhou, Huiling, Shan, Xiaohang, Chen, Lingling, Lv, Jiale, Shen, Zhongyi, Duan, Chengwei, Hu, Baoying, and Ni, Runzhou
- Published
- 2016
- Full Text
- View/download PDF
3. Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression
- Author
-
Hu, Baoying, Yan, Xia, Liu, Fang, Zhu, Changlai, Zhou, Huiling, Chen, Yuyan, Liu, Jinxia, Gu, Xingxing, Ni, Runzhou, and Zhang, Tianyi
- Published
- 2016
- Full Text
- View/download PDF
4. Expression and clinical role of NF45 as a novel cell cycle protein in esophageal squamous cell carcinoma (ESCC)
- Author
-
Ni, Sujie, Zhu, Junya, Zhang, Jianguo, Zhang, Shu, Li, Mei, Ni, Runzhou, Liu, Jinxia, Qiu, Huiyuan, Chen, Wenjuan, Wang, Huijie, and Guo, Weijian
- Published
- 2015
- Full Text
- View/download PDF
5. Decreased Expression and Prognostic Role of Mitogen-Activated Protein Kinase Phosphatase 4 in Hepatocellular Carcinoma
- Author
-
Liu, Jinxia, Ni, Wenkai, Xiao, Mingbing, Jiang, Feng, and Ni, Runzhou
- Published
- 2013
- Full Text
- View/download PDF
6. ARP3 promotes tumor metastasis and predicts a poor prognosis in hepatocellular carcinoma.
- Author
-
Lv, Jiale, Liu, Jinxia, Xu, Hui, Xu, Chenzhou, Zhang, Xuening, Tang, Lei, Zhang, Zijuan, Qu, Lishuai, Lu, Cuihua, Xiao, Mingbin, Jiang, Feng, and Zhou, Yifan
- Subjects
- *
ACTIN-related proteins , *LIVER cancer , *PROGNOSIS , *METASTASIS , *BENIGN tumors - Abstract
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Therefore, the study of the precise molecular mechanism underlying hepatocarcinogenesis has profound significance. In this study, we found that the expression of ARP3 was significantly up-regulated in HCC tissues and cell lines. Studies in liver cancer specimens showed that the expression of ARP3 is closely related to the pathological grade, distant metastasis and vascular invasion of HCC. According to the results of multivariate analysis, ARP3 is an independent prognostic factor for HCC patients. In vitro, knockdown of ARP3 expression significantly inhibited the invasion and migration of HCC cells and altered the expression of EMT markers. Based on the above conclusions, we conclude that ARP3 may be a potential prognostic indicator and therapeutic target for HCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Anxiety and serum catecholamines as predictors of survival and recurrence in hepatocellular carcinoma.
- Author
-
Liu, Jinxia, Zong, Guijuan, Zhang, Chengliang, Li, Chunsun, Chen, Xudong, and Zhang, Yixin
- Subjects
- *
ANXIETY diagnosis , *CATECHOLAMINES , *LIVER cancer , *ONCOLOGY , *MAGNETIC resonance imaging , *HEPATOCELLULAR carcinoma , *LIVER tumors , *MULTIVARIATE analysis , *PROGNOSIS , *RETROSPECTIVE studies , *PSYCHOLOGY - Abstract
Objective: Increasing evidence suggests that psychological factors are involved in tumor progression. This study investigated the influence of anxiety and serum catecholamines (CAs) on the prognosis of hepatocellular carcinoma (HCC).Method: We enrolled 110 HCC patients who underwent tumor resection at the Affiliated Hospital of Nantong University, China, in this long-term investigation between 2005 and 2009. We evaluated anxiety using the Hamilton Anxiety Rating Scale (HAMA) and analyzed CA levels using an ELISA kit. We then assessed the association of each of them with overall survival (OS) and time to recurrence (TTR), as well as with other clinical variables.Results: The HAMA scores significantly correlated with metastasis (P = 0.015), hepatitis B surface antigens (HBsAg) (P = 0.045), and the tumor-node-metastasis stage (P = 0.032), whereas the CA levels also significantly associated with tumor differentiation (P < 0.001). Univariate and multivariate analyses revealed that HAMA scores and CA levels were significant predictors of OS and TTR in HCC patients, with high levels of each being strongly correlated with poor prognosis.Conclusion: The HAMA scores and the CA levels were elevated in HCC patients and correlated with OS and TTR, suggesting that they are candidate prognostic markers of HCC. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. Long non-coding RNA SNHG20 predicts a poor prognosis for HCC and promotes cell invasion by regulating the epithelial-to-mesenchymal transition.
- Author
-
Liu, Jinxia, Lu, Cuihua, Xiao, Mingbing, Jiang, Feng, Qu, Lishuai, and Ni, Runzhou
- Subjects
- *
NON-coding RNA , *LIVER cancer patients , *LIVER cancer , *CANCER invasiveness , *EPITHELIAL cells , *MESENCHYMAL stem cells , *PROGNOSIS - Abstract
Background Recently, Accumulating evidence indicates that long noncoding RNAs (lncRNAs) have been shown to have critical regulatory roles in human tumor biology and development. However, the expression pattern and biological function of lncRNA small nucleolar RNA host gene 20 (SNHG20) in hepatocellular carcinoma (HCC) remains largely unknown. Methods The expression of SNHG20 in 96 paired HCC tissues and cell lines were detected by quantitative real-time PCR (qRT-PCR) analysis. Kaplan-Meier survival analysis and log-rank test was used to reveal the association between SNHG20 expression and the overall survival time in HCC patients. CCK8 cell proliferation and transwell invasion assays were performed to analyze the cell proliferation and cell invasion ability. QRT-PCR and western-blotting analysis were performed to demonstrate the mRNA levels and protein expression of ZEB1, ZEB2 and relative epithelial-to-mesenchymal transition (EMT) markers (E-cadherin, N-cadherin and Vimentin). Results We showed that the expression level of SNHG20 was significantly up-regulated in 96 pairs of HCC tissues and adjacent normal tissues. Higher SNHG20 expression was positively correlated with larger tumor size and advanced TNM stage, and negatively correlated with the over survival (OS) time for HCC patients. In vitro, loss-function assays revealed that knockdown of SNHG20 inhibited cell proliferation and invasion, whereas, gain-of-function promoted cell proliferation and invasion. Furthermore, knockdown of SNHG20 inhibited ZEB1, ZEB2, N-cadherin and Vimentin expression and up-regulated the E-cadherin expression in HCC cells. Mechanistic investigation revealed that SNHG20 could bind to enhancer of zeste homolog 2 (EZH2) and regulated E-cadherin expression. Conclusion Our results showed that the SNHG20/EZH2/E-cadhein regulator pathway might contribute to the development of novel therapeutic strategies for HCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Decreased Expression of EHD2 Promotes Tumor Metastasis and Indicates Poor Prognosis in Hepatocellular Carcinoma.
- Author
-
Liu, Jinxia, Ni, Wenkai, Qu, Lishuai, Cui, Xiaopeng, Lin, Zhipeng, Liu, Qingqing, Zhou, Huiling, and Ni, Runzhou
- Subjects
- *
METASTASIS , *KAPLAN-Meier estimator , *IMMUNOFLUORESCENCE , *LIVER cancer patients , *LIVER cancer , *PROGNOSIS , *CARRIER proteins , *CELL motility , *FLUORESCENT antibody technique , *GLYCOPROTEINS , *HEPATOCELLULAR carcinoma , *IMMUNOHISTOCHEMISTRY , *LIVER tumors , *SURVIVAL , *WESTERN immunoblotting , *PRECIPITIN tests , *TUMOR grading - Abstract
Background: Metastasis remains the most common cause of lethal outcomes in hepatocellular carcinoma (HCC) after curative resection. Understanding molecular mechanisms that regulate metastasis process is crucial for improving treatment of hepatocellular carcinoma.Aims: In this article, we examined whether Eps15 homology domain-containing 2 (EHD2) played a critical role in hepatocellular carcinoma metastasis and explored the possible mechanism.Methods: EHD2 and E-cadherin expression levels in hepatocellular carcinoma patients were examined using Western blotting and immunohistochemistry. The cell migration and invasion were evaluated by wound-healing assay and trans-well assay. Epithelial-mesenchymal transition was analyzed by immunofluorescence, and the vital markers were detected by Western blotting. The correlation of EHD2 and E-cadherin was confirmed by co-immunoprecipitation.Results: EHD2 expression, along with the epithelial marker E-cadherin, was markedly reduced in tumor tissues than in adjacent noncancerous tissues. Moreover, EHD2 was positively correlated with E-cadherin, histological grade, tumor metastasis, and microvascular invasion. Kaplan-Meier survival analysis showed that hepatocellular carcinoma patients with decreased EHD2 expression had shorter overall survival times than those with higher EHD2 expression. Knockdown of EHD2 induced an increase in cell invasion and changes characteristic of epithelial-mesenchymal transition, while overexpression of EHD2 inhibited these processes.Conclusions: Molecular data indicated that EHD2 inhibited migration and invasion of hepatocellular carcinoma probably by interacting with E-cadherin and it might be an independent, significant risk factor for survival after curative resection. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
10. GAB2 promotes cell proliferation by activating the ERK signaling pathway in hepatocellular carcinoma.
- Author
-
Chen, Yuyan, Liu, Qingqing, Wu, Miaomiao, Li, Manhua, Ding, Haifang, Shan, Xiaohang, Liu, Jinxia, Tao, Tao, Ni, Runzhou, and Chen, Xudong
- Abstract
Grb2-associated binding protein 2 (GAB2), a key member of the family of Gab scaffolding adaptors, is important in the phospoinositide3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) signaling pathways, and is closely associated with cell proliferation, cell transformation, and tumor progression. But its role in hepatocellular carcinoma (HCC) is still unknown. In this study, we investigated the expression of GAB2 and its potential clinical and biological significances in HCC. Western bolt and immunohistochemistrical analyses revealed that GAB2 was obviously upregulated in HCC tissues. Meanwhile, GAB2 was significantly associated with histological grade, tumor size, and the proliferation marker Ki-67 through our further analysis. The Kaplan-Meier survival curves also showed that increased GAB2 expression was directly correlated with poor prognosis in HCC patients and served as an independent prognostic marker of overall survival. Moreover, serum starvation-refeeding, RNA interference, CCK-8, EDU, colony formation, and flow-cytometry analyses were all performed with the purpose of investigating GAB2's regulation of HCC cell proliferation. Our results indicated that GAB2 progressively accumulated when cells entered into S phase. Consistently, cell proliferation was distinctly hindered by small interfering RNA. More interestingly, we discovered that GAB2 promoted cell proliferation by enhancing ERK signaling and GAB2-induced cell proliferation was inhibited by the inhibition of ERK activation. Finally, GAB2 was verified to be able to confer doxorubicin resistance in HCC cells. In summary, these data demonstrated that GAB2 might promote HCC cell proliferation by enhancing ERK signaling, and all above findings provided a potential therapeutic strategy for the treatment of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
- Author
-
Liu, Jinxia, Cui, Xiaopeng, Qu, Lishuai, Hua, Lu, Wu, Miaomiao, Shen, Zhongyi, Lu, Cuihua, and Ni, Runzhou
- Subjects
- *
PROTEIN expression , *SORAFENIB , *LIVER cancer , *LIVER cancer patients , *BIOMARKERS , *HOMEOBOX proteins , *PROLIFERATING cell nuclear antigen , *PROGNOSIS - Abstract
The mechanism underlying poor prognosis and sorafenib resistance in patients with hepatocellular carcinoma (HCC) is unknown and, to date, no useful predictive biomarkers of sorafenib resistance have been identified. Distal-less homeobox 2 (DLX2) is a transcription factor involved in cell cycle regulation that is closely correlated with cancer prognosis. In this study, we showed that DLX2 is overexpressed in HCC tissues and cell lines and that the level of DLX2 overexpression is positively correlated with histological grade, metastasis and Ki67 expression, which are indicators of poor prognosis. We also found that DLX2 accumulates in proliferating HCC cells, where it is associated with the expression of proliferating cell nuclear antigen (PCNA), Cyclin D1 and Cyclin A. Flow cytometry and cell counting kit-8 (CCK-8) assays indicated that DLX2 depletion causes cell cycle arrest at the G1 phase and hinders cell proliferation. Moreover, the sensitivity of HCC cells to sorafenib is restored when the DLX2 gene is knocked down using a short interfering RNA. We demonstrated that DLX2 facilitates sorafenib resistance by promoting the expression of markers of epithelial–mesenchymal transition and by activating the extracellular signal-regulated protein kinase pathway. Our findings reveal that DLX2 plays a regulatory role in HCC cell proliferation and suggests that targeting DLX2 represents a novel strategy to increase sorafenib efficacy in the management of HCC. In conclusion, DLX2 is a novel marker of poor prognosis and sorafenib resistance in patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
- Author
-
Hua, Lu, Hu, Baoying, Yan, Daliang, Liu, Jinxia, Shen, Yifen, Zhao, Fengbo, Shen, Chaoyan, Chen, Buyou, and Cui, Xiaopeng
- Subjects
- *
NUCLEAR proteins , *SORAFENIB , *LIVER cancer , *GENE expression , *GENETIC overexpression , *APOPTOSIS - Abstract
Nucleostemin (NS)/GNL3 protein has been recently documented to be a nucleolar protein that was abundantly expressed in stem cells and cancer cells. Herein, we showed that NS was upregulated in HCC tissues and the expression of NS was inversely correlated with that of p53. Overexpression of NS predicted significantly worsened prognosis in HCC patients, suggesting that NS might serve as a prognostic marker of HCC. In addition, we found that depletion of NS sensitized HCC cells to sorafenib-induced apoptosis. Moreover, we found that the mechanism underlying NS-mediated sorafenib resistance involved dysregulated expression of p53, and downstream Bax and Bcl-2 proteins. NS interacted with p53 in HCC cells. Depletion of NS increased the expression of p53 and Bax, whereas impaired the level of cellular Bcl-2. Interference of NS enhanced the cytotoxic effects of sorafenib in HCC cells. Furthermore, ectopic expression of NS impaired the apoptosis of HCC cells following sorafenib exposure. Therefore, NS may contribute to sorafenib resistance in HCC cells through the modulation of p53 pathway and Bcl-2 proteins. These findings indicated that the combination of silencing NS expression and sorafenib treatment is a promising therapeutic strategy in treatment of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. High VRK1 expression contributes to cell proliferation and survival in hepatocellular carcinoma.
- Author
-
Huang, Wei, Cui, Xiaopeng, Chen, Yuyan, Shao, Mengting, Shao, Xian, Shen, Yifen, Liu, Qingqing, Wu, Miaomiao, Liu, Jinxia, Ni, Wenkai, Lu, Cuihua, and Wan, Chunhua
- Subjects
- *
GENE expression , *CANCER cell proliferation , *LIVER cancer , *SERINE/THREONINE kinases , *CELL cycle regulation , *BIOMARKERS - Abstract
VRK1 is a member of the vaccinia-related kinase (VRK) family of serine/threonine protein kinases, which is known to play multiple roles in cellular proliferation, cell cycle regulation and carcinogenesis. However, the expression and physiological significance of VRK1 in hepatocellular carcinoma (HCC) remain unclear. In this study, we aimed to investigate the potential role of VRK1 in the development and progression of HCC. Western blot and immunohistochemical analysis revealed that VRK1 was highly expressed in HCC tissues and cell lines, compared with adjacent nontumorous tissues and LO2 normal hepatocytes. Meanwhile, clinicopathological analysis showed that VRK1 was significantly associated with AJCC stage, Ki-67 and a poor prognosis in HCC specimens. Univariate and multivariate analysis showed that VRK1 could serve as an independent prognostic indicator of HCC patients’ survival. Furthermore, we found that VRK1 was lowly expressed in serum-starved Huh7 cells, and was progressively increased after serum-refeeding. Finally, flow cytometry, CCK-8 and colony formation assay indicated that the depletion of VRK1 could retard cell cycle progression and reduce cells proliferation in HCC cells. On the basis of these findings, we conclude that VRK1 may be a candidate prognostic biomarker as well as a potential therapeutical target of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.
- Author
-
Zhang, Xiubing, Xu, Pan, Ni, Wenkai, Fan, Hui, Xu, Jian, Chen, Yongmei, Huang, Wei, Lu, Shumin, Liang, Li, Liu, Jinxia, Chen, Buyou, and Shi, Weidong
- Subjects
- *
OXALIPLATIN , *LIVER cancer , *DRUG resistance in cancer cells , *GENE expression , *MOLECULAR genetics , *PROGNOSIS - Abstract
We aimed to investigate the molecular mechanisms of DYRK2 and the HCC sensitivity to Oxaliplatin in DYRK2-depleted HCC cells. HCC tissue specimens were obtained from 86 HCC patients during hepatectomy. We used immunohistochemistry and western blot to analyze DYRK2 expression in HCC tissues and cell lines, and used siRNA transfection to decrease DYRK2 expression in HCC cells. Flow cytometry and CCK-8 assay were detected in cell cycle progression, cell proliferation and the efficacy of Oxaliplatin, DYRK2 was down-regulated in HCC tissues, compared with adjacent nontumor ones. The significant correlation between DYRK2 expression and clinicopathologic factors was apparently shown in the immunohistochemical and statistical analyses. The expression of DYRK2 was significantly associated with histological grade of HCC patients. Univariate and multivariate survival analyses revealed that DYRK2 was a significant predictor for overall survival of HCC patients. The depletion of DYRK2 promoted HCC cell proliferation, and increased resistance to Oxaliplatin. These data showed that the downregulated expression of DYRK2 in HCC tumor tissues could promote the proliferation of HCC cells. In addition, reducing DYRK2 expression was associated with poor prognosis and Oxaliplatin resistance in HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.